NGS For GMP Compliance: New Guidelines, New Tools
How can laboratories implement NGS-based adventitious agent detection while meeting regulatory expectations for data integrity and traceability? Sequencing-based analysis in biologics production brings regulatory expectations for data integrity, audit trails, and user authentication into sharp focus. ICH Q5A(R2), FDA 21 CFR Part 11, and European Pharmacopoeia Chapter 2.6.41 each provide relevant guidance or requirements for implementing NGS-based testing and managing data in a GxP environment. These requirements align with capabilities in QIAGEN CLC Genomics Workbench and Server, including features designed to support controlled access, traceability, and reliable data management.
In this on-demand webinar, Dr. Erika Toth, Account Manager at QIAGEN Digital Insights, draws on over 15 years of experience in biomedical sciences and her expertise in GMP-compliant bioinformatics to explain how regulatory requirements translate into practical NGS workflows for biopharmaceutical testing.
Watch the full webinar to explore how current regulatory guidelines relate to QIAGEN bioinformatics solutions and the implementation of NGS-based testing in GxP environments.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.